tetano
Editor, Senior Moderator
Int J Infect Dis
. 2025 Jul 12:107983.
doi: 10.1016/j.ijid.2025.107983. Online ahead of print. Comparable Effectiveness of MF59®-Adjuvanted and High-Dose Quadrivalent Inactivated Influenza Vaccines for Prevention of Test-Confirmed Influenza During the 2022-2023 Influenza Season
Mahrukh Imran[SUP] 1 [/SUP], Benjamin Chastek[SUP] 2 [/SUP], Tim Bancroft[SUP] 2 [/SUP], Noah Webb[SUP] 2 [/SUP], Stephen I Pelton[SUP] 3 [/SUP], Mendel D M Haag[SUP] 4 [/SUP], Ian McGovern[SUP] 5 [/SUP]
Affiliations
Objective: Adjuvanted and higher-dose influenza vaccines are recommended by the US Advisory Committee on Immunization Practices (ACIP) for adults ≥65 years. This study estimated the relative vaccine effectiveness (rVE) of adjuvanted quadrivalent influenza vaccine (aQIV) versus high-dose QIV (HD-QIV) in preventing test-confirmed influenza in US adults ≥65 years during the 2022-2023 season.
Methods: In a retrospective test-negative design, electronic health records and claims data from the Optum Market Clarity database were used to identify adults ≥65 years who received aQIV or HD-QIV and were tested for influenza associated with acute respiratory or febrile illness in any setting or during emergency department visits or inpatient admissions (ED/inpatient). A doubly robust model was used, combining inverse probability of treatment weighting and logistic regression.
Results: Of 4,228,481 adults ≥65 years who received aQIV or HD-QIV, 30,911 were tested for influenza and met selection criteria (2,361 cases; 28,550 controls). The rVE of aQIV vs. HD-QIV was -2.5% (95% CI, -13.4% to 7.4%) in any setting and 0.0% (95% CI, -15.9% to 13.7%) in ED/inpatient settings.
Conclusions: Similar to previous studies, aQIV and HD-QIV provided comparable protection against test-confirmed influenza in any setting, including ED/inpatient, aligning with ACIP and other recommendations for adults ≥65 years.
Keywords: adjuvanted influenza vaccine; high-dose influenza vaccine; older adults aged ≥65 years; real-world data; test-confirmed influenza, laboratory-confirmed influenza; test-negative design.
. 2025 Jul 12:107983.
doi: 10.1016/j.ijid.2025.107983. Online ahead of print. Comparable Effectiveness of MF59®-Adjuvanted and High-Dose Quadrivalent Inactivated Influenza Vaccines for Prevention of Test-Confirmed Influenza During the 2022-2023 Influenza Season
Mahrukh Imran[SUP] 1 [/SUP], Benjamin Chastek[SUP] 2 [/SUP], Tim Bancroft[SUP] 2 [/SUP], Noah Webb[SUP] 2 [/SUP], Stephen I Pelton[SUP] 3 [/SUP], Mendel D M Haag[SUP] 4 [/SUP], Ian McGovern[SUP] 5 [/SUP]
Affiliations
- PMID: 40659177
- DOI: 10.1016/j.ijid.2025.107983
Objective: Adjuvanted and higher-dose influenza vaccines are recommended by the US Advisory Committee on Immunization Practices (ACIP) for adults ≥65 years. This study estimated the relative vaccine effectiveness (rVE) of adjuvanted quadrivalent influenza vaccine (aQIV) versus high-dose QIV (HD-QIV) in preventing test-confirmed influenza in US adults ≥65 years during the 2022-2023 season.
Methods: In a retrospective test-negative design, electronic health records and claims data from the Optum Market Clarity database were used to identify adults ≥65 years who received aQIV or HD-QIV and were tested for influenza associated with acute respiratory or febrile illness in any setting or during emergency department visits or inpatient admissions (ED/inpatient). A doubly robust model was used, combining inverse probability of treatment weighting and logistic regression.
Results: Of 4,228,481 adults ≥65 years who received aQIV or HD-QIV, 30,911 were tested for influenza and met selection criteria (2,361 cases; 28,550 controls). The rVE of aQIV vs. HD-QIV was -2.5% (95% CI, -13.4% to 7.4%) in any setting and 0.0% (95% CI, -15.9% to 13.7%) in ED/inpatient settings.
Conclusions: Similar to previous studies, aQIV and HD-QIV provided comparable protection against test-confirmed influenza in any setting, including ED/inpatient, aligning with ACIP and other recommendations for adults ≥65 years.
Keywords: adjuvanted influenza vaccine; high-dose influenza vaccine; older adults aged ≥65 years; real-world data; test-confirmed influenza, laboratory-confirmed influenza; test-negative design.